Pancreatic Cancer Research

ResearcherNational Cancer Centre JapanActive in the last 2 years

Atsushi Ochiai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6857-4009; OpenAlex author ID A5038375140, A5126487436. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 13)
Trials
0
Grants
0
Labs led
2
Collaborators
38
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 2 papers

Papers 18

  1. MIF-CD74 axis facilitates MDSC infiltration in the tumor microenvironment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2026.218348↗
  2. Corrigendum to "MIF-CD74 axis facilitates MDSC infiltration in the tumor microenvironment of pancreatic ductal adenocarcinoma" [Cancer Lett. 645, (2026), 21834… Co-author DOI 10.1016/j.canlet.2026.218794↗
  3. Fibroblast inhibition by tocilizumab enabled gemcitabine/nab-paclitaxel rechallenge for pancreatic cancer. Co-author DOI 10.1111/cas.15929↗
  4. Interleukin 6/gp130 axis promotes neural invasion in pancreatic cancer. Last author DOI 10.1002/cam4.4823↗
  5. A Comparative Study of Patient-Derived Tumor Models of Pancreatic Ductal Adenocarcinoma Involving Orthotopic Implantation. Last author DOI 10.1159/000521714↗
  6. Clinical and Tumor Characteristics of Patients with High Serum Levels of Growth Differentiation Factor 15 in Advanced Pancreatic Cancer. Last author DOI 10.3390/cancers13194842↗
  7. The "histological replacement growth pattern" represents aggressive invasive behavior in liver metastasis from pancreatic cancer. Last author DOI 10.1002/cam4.2954↗
  8. Novel stromal biomarker screening in pancreatic cancer patients using the in vitro cancer-stromal interaction model. Last author DOI 10.1186/s12876-020-01556-w↗
  9. Development and Biological Analysis of a Novel Orthotopic Peritoneal Dissemination Mouse Model Generated Using a Pancreatic Ductal Adenocarcinoma Cell Line. Co-author DOI 10.1097/mpa.0000000000001253↗
  10. Expression of Monocarboxylate Transporter 1 Is Associated With Better Prognosis and Reduced Nodal Metastasis in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000001369↗
  11. Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer. Last author DOI 10.1007/s00520-018-4248-4↗
  12. Neural Invasion Spreads Macrophage-Related Allodynia via Neural Root in Pancreatic Cancer. Last author DOI 10.1213/ane.0000000000002803↗
  13. C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000000465↗
  14. Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels. Last author DOI 10.1097/mpa.0000000000000335↗
  15. [A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic … Co-author PMID 25812499↗
  16. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Last author DOI 10.1038/bjc.2013.174↗
  17. Neural invasion induces cachexia via astrocytic activation of neural route in pancreatic cancer. Last author DOI 10.1002/ijc.27594↗
  18. RAS oncogenic signal upregulates EZH2 in pancreatic cancer. Last author DOI 10.1016/j.bbrc.2011.12.099↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shuichi Mitsunaga · 11 shared papers, 2012–2023 · strength 0.90
  2. Masafumi Ikeda · 11 shared papers, 2012–2023 · strength 0.90
  3. Kazunori Aoki · 3 shared papers, 2023–2026 · strength 0.55
  4. Hiroyuki Tsunoda · 3 shared papers, 2023–2026 · strength 0.55
  5. Hidetaka Suzuki · 4 shared papers, 2018–2022 · strength 0.46
  6. Keisuke Sekine · 2 shared papers, 2026 · strength 0.40
  7. Satoshi Nara · 2 shared papers, 2026 · strength 0.40
  8. Hironori Fukuda · 2 shared papers, 2026 · strength 0.40
  9. Nobuyoshi Hiraoka · 2 shared papers, 2026 · strength 0.40
  10. Minoru Esaki · 2 shared papers, 2026 · strength 0.40
  11. Motohiro Kojima · 3 shared papers, 2019–2020 · strength 0.35
  12. Tomofumi Miura · 4 shared papers, 2015–2021 · strength 0.35
  13. Naoto Gotohda · 2 shared papers, 2019–2020 · strength 0.25
  14. Yasunori Nishida · 2 shared papers, 2019–2020 · strength 0.25
  15. Kazuyoshi Yanagihara · 2 shared papers, 2019–2022 · strength 0.25
  16. Toshio Seyama · 2 shared papers, 2019–2022 · strength 0.25
  17. Hiroshi Yokozaki · 2 shared papers, 2019–2022 · strength 0.25
  18. Takanori Kubo · 2 shared papers, 2019–2022 · strength 0.25
  19. Kazuo Watanabe · 2 shared papers, 2020–2023 · strength 0.25
  20. Mitsuhito Sasaki · 2 shared papers, 2020–2023 · strength 0.25
  21. Hiroshi Imaoka · 2 shared papers, 2020–2023 · strength 0.25
  22. Tetsuo Akimoto · 2 shared papers, 2019–2020 · strength 0.21
  23. Mami Takahashi · 1 shared paper, 2026 · strength 0.20
  24. Ai Irisawa · 2 shared papers, 2018–2020 · strength 0.18
  25. Toshihiro Yamaguchi · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.